PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

被引：0
|
作者：
Schettini, F. [1 ]
Pascual, T. [1 ]
Chic, N. [1 ]
Conte, B. [2 ]
Martinez, O. [1 ]
Adamo, B. [1 ]
Vidal, M. [1 ]
Munoz, M. [1 ]
Fernandez-Martinez, A. [3 ]
Griguolo, G. [4 ]
Guarneri, V. [4 ]
Conte, P. F. [4 ]
De Placido, S. [5 ]
Carey, L. [6 ]
Perou, C. M. [7 ]
Prat, A. [1 ]
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[2] Univ Genoa, Osped Policlin San Martino, Med Oncol, Genoa, Italy
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol, Padua, Italy
[5] Azienda Univ Osped Federico II, Clin Med & Surg, Naples, Italy
[6] UNC, Lineberger Canc Ctr, Med, Div Hematol Oncol, Chapel Hill, NC USA
[7] UNC, Lineberger Canc Ctr, Genet, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
    Schettini, Francesco
    Pascual, Tomas
    Conte, Benedetta
    Chic, Nuria
    Braso-Maristany, Fara
    Galvan, Patricia
    Martinez, Olga
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Fernandez-Martinez, Aranzazu
    Rognoni, Carla
    Griguolo, Gaia
    Guarneri, Valentina
    Conte, Pier Franco
    Locci, Mariavittoria
    Brase, Jan C.
    Gonzalez-Farre, Blanca
    Villagrasa, Patricia
    De Placido, Sabino
    Schiff, Rachel
    Veeraraghavan, Jamunarani
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Pernas, Sonia
    Perou, Charles M.
    Carey, Lisa A.
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2020, 84
  • [2] Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer
    Braso-Maristany, F.
    Griguolo, G.
    Llombart-Cussac, A.
    Pascual, T.
    Pare, L.
    Bermejo, B.
    Oliveira, M.
    Morales, S.
    Martinez, N.
    Vidal, M.
    Pernas, S.
    Lopez, R.
    Munoz, M.
    Galvan, P.
    Garau, I.
    Manso, L.
    Alarcon, J.
    Martinez, E.
    Villagrasa, P.
    Cortes, J.
    Prat, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
    Shen, Guoshuang
    Zhao, Fuxing
    Huo, Xingfa
    Ren, Dengfeng
    Du, Feng
    Zheng, Fangchao
    Zhao, Jiuda
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] PAM50 HER2-Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2-Positive Breast Cancer.
    Cheang, M. C. U.
    Prat, A.
    Fan, C.
    Perou, C. M.
    CANCER RESEARCH, 2011, 71
  • [5] PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer
    Vidal, M.
    de la Pena, L.
    Oliveira, M.
    Cortes, J.
    Llombart, A.
    Prat, A.
    CANCER RESEARCH, 2013, 73
  • [6] PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
    Vidal, Maria
    De La Pena, Lorena
    Oliveira, Mafalda
    Cortes, Javier
    Llombart, Antonio
    Prat, Aleix
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
    Pascual, T.
    Bermejo De Las Heras, B.
    Martinez, N.
    Oliveira, M.
    Pernas Simon, S.
    Lopez Lopez, R.
    Ruiz Cabrero, I.
    Alarcon, J. D.
    Martinez De Duenas, E.
    Malon Gimenez, D.
    Gonzalez Cao, M.
    Manso Sanchez, L. M.
    Morales Murillo, S.
    Lopez de Ceballos, H.
    Cortes, J.
    Llombart Cussac, A.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S168 - S168
  • [8] Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer
    Prat, Aleix
    De Angelis, Carmine
    Pascual, Tomas
    Gutierrez, Carolina
    Wang, Tao
    Pare, Laia
    Rexer, Brent
    Cortes, Javier
    Forero, Andres
    Llombart, Antonio
    Wolff, Antonio C.
    Krop, Ian
    Galvan, Patricia
    Pavlick, Anne C.
    Villagrasa, Patricia
    Hilsenbeck, Susan G.
    Schiff, Rachel
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    CANCER RESEARCH, 2018, 78 (04)
  • [9] PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer
    Pernas, Sonia
    Petit, Anna
    Climent, Fina
    Pare, Laia
    Perez-Martin, Javier
    Ventura, Luz
    Galvan, Patricia
    Falo, Catalina
    Morilla, Idoia
    Fernandez-Ortega, Adela
    Stradella, Agostina
    Pascual, Tomas
    Gil-Gil, Miguel
    Prat, Aleix
    CANCER RESEARCH, 2018, 78 (04)
  • [10] HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
    Prat, Aleix
    Pascual, Tomas
    De Angelis, Carmine
    Gutierrez, Carolina
    Llombart-Cussac, Antonio
    Wang, Tao
    Cortes, Javier
    Rexer, Brent
    Pare, Laia
    Forero, Andres
    Wolff, Antonio C.
    Morales, Serafin
    Adamo, Barbara
    Braso-Maristany, Fara
    Vidal, Maria
    Veeraraghavan, Jamunarani
    Krop, Ian
    Galvan, Patricia
    Pavlick, Anne C.
    Bermejo, Begona
    Izquierdo, Miguel
    Rodrik-Outmezguine, Vanessa
    Reis-Filho, Jorge S.
    Hilsenbeck, Susan G.
    Oliveira, Mafalda
    Vittoria Dieci, Maria
    Griguolo, Gaia
    Fasani, Roberta
    Nuciforo, Paolo
    Parker, Joel S.
    Conte, PierFranco
    Schiff, Rachel
    Guarneri, Valentina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (01): : 46 - 54
12345